Intrinsic Value

2N3 price has not been updated for more than 7 years. This may indicate that the stock has been delisted.
2N3 doesn't have a meaningful market cap.

The intrinsic value of LNA Sante SA (2N3) under the Base Case is 14.78 EUR per share. Compared with the current market price of 23.6 EUR, the stock appears Overvalued by 37% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

2N3 Intrinsic Value
€14.78
Overvaluation 37%
Intrinsic Value
Price €23.6

We don’t have enough historical valuation data to make this comparison.

Monitor 2N3
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value €11.82
Get notified when the price drops into your buy zone
Current Price €23.6
Intrinsic Value €14.78
Margin of Safety 20% €11.82
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Alternatives to 2N3

Fundamental Analysis

What LNA Sante Does

Health Care

LNA Sante SA is a French healthcare group that runs care homes, rehabilitation clinics, and home-care services for older adults and people who need ongoing medical support. It focuses on day-to-day care such as long-term nursing care, post-acute rehabilitation, assisted living, and support for patients who can be treated outside a hospital. The company’s business is built around providing housing, nursing, therapy, and medical supervision in settings designed for people who need structured care over weeks, months, or longer.

Headquarters
France FR
Employees
8 976
IPO date
Jun 6, 2006
Read the full company overview
View Company Overview
Financials
Efficiency

Earnings Waterfall
LNA Sante SA

Wall St Price Targets

Capital Returns

Competitive Landscape

What is the Intrinsic Value of one 2N3 stock?

The intrinsic value for LNA Sante SA (2N3) under the Base Case is 14.78 EUR.

Is 2N3 stock undervalued or overvalued?

Compared with the current market price of 23.6 EUR, the stock appears Overvalued by 37% .

Back to Top